News | May 30, 2022
Glenmark Pharma reports revenue growth of 5.6% YoY in Q4
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The integration and transition of the brands are expected to be completed by June 2022.
Subscribe To Our Newsletter & Stay Updated
